Address: Actavis Gmbh,Münchner Bundesstrasse 142,5020 Salzburg,Austria
Tel: +43 662 435 235 00
Web: http://www.actavis.com/en/default.htm
Since our founding as a U.S. generic pharmaceutical company in 1984, Watson has evolved to become one of the world’s leading and most respected integrated global pharmaceutical companies. Today, Watson operates three businesses: Global Generics, Global Brands and Anda Distribution. Our Global Generics business markets approximately 190 prescription pharmaceutical families in the U.S with a significant number of product families internationally. Our Global Brands business markets more than 30 brand pharmaceutical products. Watson’s Anda Distribution business distributes products for over 200 suppliers and is focused on providing next-day delivery and responsive service to customers.
Watson develops, manufactures and markets a broad array of generic and brand pharmaceuticals that are improving the quality of life of people around the world.
Earlier this year the company set a crucial step in its internationalization strategy with the acquisition of Ascent. Would you outline the significance of the acquisition within Watson’s global expansion…
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since…
Watson is one the largest generic players in the US but the international presence of the company is still relatively modest. Watson does not have commercial operations in India but…
In an exclusive new podcast, DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of New South Wales, Medicine, St. Vincent’s Hospital) and John Skeritt, Head of Australia’s Therapeutic Goods Administration (TGA),…
Janssen Australia & New Zealand’s Bruce Goodwin argues that greater adoption of patient-centric practices is beneficial to patients, companies and healthcare systems as a whole. Goodwin also gives his five…
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Would you begin by outlining the role & importance of George Clinical within the George Institute, highlighting recent milestones & achievements? George Clinical is an important division of the Institute,…
Would you begin by giving an introduction to our international readers of the institute, highlighting recent milestones & achievements and the current focus areas of its research activities? Broadly speaking,…
For those that are not familiar with your name, would you start by introducing yourself? After obtaining my PhD in cardiovascular physiology I moved to Boston to work at MIT…
Rare Voices Australia is a new organisation that has been established after the national rare diseases symposium in 2011. Can you please begin with giving our readers an introduction to…
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Speaking to the Australian environment, how would you rate the market in terms of companies like Swisse? After traveling the world, the Australian market has shown to be one of…
In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that…
Dr Bernadette Morris-Smith has also participated in this interview TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would you begin…
See our Cookie Privacy Policy Here
